Skip to main content

Advertisement

Table 2 Baseline characteristics of subjects

From: Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study

  Mean ± SD or median (min,max) or number (%) p value
Group 1 (n = 11) Group 2 (n = 9) Group 3 (n = 8) Group 4 (n = 8)
Age, year 47.94 ± 7.73 45.33 ± 8.66 41.12 ± 7.72 43.00 ± 7.41 0.23b
BMI, kg/m2 22.48 ± 2.40 22.68 ± 3.64 23.63 ± 3.07 21.61 ± 2.45 0.59b
Male, no. 8 (72.7) 7 (77.8) 4 (50) 4 (50) 0.48c
Diabetes, no. 0 1 (11.1) 0 0 0.41c
Hypertension, no 1 (9.1) 1 (11.1) 0 0 0.48c
PIs, no. 2 (18.2) 1 (11.1) 0 1 (12.5) 0.50c
NNRTI, no. 9 (81.8) 8 (88.9) 8 (100) 7 (87.5)
Suppressed HIV viral load, nod 9 (81.8) 8 (88.9) 8 (100) 8 (100) 0.27c
HIV duration, years 5.61 ± 5.21 11.11 ± 3.79 6.61 ± 4.51 8.78 ± 7.11 0.13b
CD4, cell/cmm 514.27 ± 331.71 678.22 ± 438.85 612.62 ± 270.87 443.88 ± 152.96 0.45b
Creatinine, mg/dL 0.90 ± 0.19 0.95 ± 0.28 0.94 ± 0.35 0.73 ± 0.13 0.29b
SGPT, mg/dL 35.81 ± 24.46 35.66 ± 15.02 30.13 ± 12.77 27.50 ± 8.18 0.67b
HDL-c, mg/dL 52.07 ± 13.23 53.04 ± 12.08 57.73 ± 20.93 58.13 ± 23.15 0.83b
LDL-c, mg/dL 175.75 ± 36.90 186.99 ± 24.60 163.01 ± 9.65 173.04 ± 35.24 0.43b
TC, mg/dL 222.0 (197,301) 245.0 (227,353) 242.5 (191,285) 242.0 (202,297) 0.48a
TG, mg/dL 134.0 (64,390) 176.00 (53,620) 106.50 (58,499) 109.0 (52,367) 0.54a
CPK, mg/dL 131.0 (46,876) 150.0 (87,234) 133.5 (60,289) 123.0 (79,532) 0.96a
  1. Group 1, pravastatin then combination; Group 2, combination then pravastatin; Group 3, phytosterols then combination; Group 4, combination then phytosterols.
  2. aKruskal–Wallis Test.
  3. bOne-way ANOVA.
  4. cLikelihood Ratio test.
  5. dSuppressed HIV viral load defined by HIV viral load <50 copies/ml.